Annunziata Di Domenico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annunziata Di Domenico has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Aurel Perren
University of Bern
29 shared publications - Ilaria Marinoni
Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
29 shared publications - Iacovos Prodromos Michael
Sunnybrook Research Institute, Toronto, ON, Canada
23 shared publications - Sadegh Saghafinia
Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland
23 shared publications Giovanni Ciriello
13 shared publicationsKrisztian Homicsko
13 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by Springer Nature in Endocrine Pathology
- Vol. 36 (1) , 47
Correction to: Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1/DAXX/ATRX Explain Biological Variability
- 26 November 2025
- Published by Springer Nature in Endocrine Pathology
- Vol. 36 (1) , 47
Open AccessCorrection to: Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1/DAXX/ATRX Explain Biological Variability
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics approaches, we revealed that MLP tumors arise from IT via dedifferentiation following a reverse trajectory along the developmental pathway of islet β cells, which results in the acquisition of a progenitor-like molecular phenotype. Functionally, the miR-181cd cluster induces the IT-to-MLP transition by suppressing expression of the Meis2 transcription factor, leading to upregulation of a developmental transcription factor, Hmgb3. Notably, the IT-to-MLP transition constitutes a distinct step of tumorigenesis and is separable from the classic proliferation-associated hallmark, temporally preceding accelerated proliferation of cancer cells. Furthermore, patients with PanNET with elevated HMGB3 expression and an MLP transcriptional signature are associated with higher-grade tumors and worse survival. Overall, our results unveil a new mechanism that modulates cancer cell plasticity to enable malignant progression.Significance:Dedifferentiation has long been observed as a histopathologic characteristic of many cancers, albeit inseparable from concurrent increases in cell proliferation. Herein, we demonstrate that dedifferentiation is a mechanistically and temporally separable step in the multistage tumorigenesis of pancreatic islet cells, retracing the developmental lineage of islet β cells.This article is highlighted in the In This Issue feature, p. 2355
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics approaches, we revealed that MLP tumors arise from IT via dedifferentiation following a reverse trajectory along the developmental pathway of islet β cells, which results in the acquisition of a progenitor-like molecular phenotype. Functionally, the miR-181cd cluster induces the IT-to-MLP transition by suppressing expression of the Meis2 transcription factor, leading to upregulation of a developmental transcription factor, Hmgb3. Notably, the IT-to-MLP transition constitutes a distinct step of tumorigenesis and is separable from the classic proliferation-associated hallmark, temporally preceding accelerated proliferation of cancer cells. Furthermore, patients with PanNET with elevated HMGB3 expression and an MLP transcriptional signature are associated with higher-grade tumors and worse survival. Overall, our results unveil a new mechanism that modulates cancer cell plasticity to enable malignant progression.Significance:Dedifferentiation has long been observed as a histopathologic characteristic of many cancers, albeit inseparable from concurrent increases in cell proliferation. Herein, we demonstrate that dedifferentiation is a mechanistically and temporally separable step in the multistage tumorigenesis of pancreatic islet cells, retracing the developmental lineage of islet β cells.This article is highlighted in the In This Issue feature, p. 2355
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression